All > Sbrt

Non-ablative SBRT for Non-Small Cell Lung Cancer

University of Kansas Medical Center, Kansas City, KS
Non-Small Cell Lung CancerNon-ablative SBRT - Radiation
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study the effects of radiation on the immune system in patients with early stage lung cancer who are surgical candidates. Tumor, normal tissue and blood specimens will be analyzed for changes in the immune system.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
N/A

Similar Trials

1
Carboplatin
1
Papaverine
1
Papaverine Hydrochloride

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: through study completion, an average of 18 months

Month 36
Loco-regional control disease
Metastasis-free survival
Overall survival
Month 6
Impact of SBRT on post-surgical wound healing complication rate assessed by CTCAE v5
The impact of pre-surgical non-ablative SBRT on peri- and post-operative surgical complication rate
Month 18
Changes in tumor T cell repertoire following pre and post SBRT

Trial Safety

Phase-Based Safety

1 of 3

Similar Trials

1
Carboplatin
1
Papaverine
1
Papaverine Hydrochloride

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

Non-ablative SBRT
1 of 1

Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Non-ablative SBRT · No Placebo Group · N/A

Non-ablative SBRT
Radiation
Experimental Group · 1 Intervention: Non-ablative SBRT · Intervention Types: Radiation

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 18 months

Who is running the clinical trial?

University of Kansas Medical CenterLead Sponsor
412 Previous Clinical Trials
160,703 Total Patients Enrolled
Shalina Gupta-Burt, MDPrincipal InvestigatorUniversity of Kansas Medical Center

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
The tumor should be at least 2 cm away from the bronchial margin and 1 cm away from the visceral pleura. It should also be located in a spot that can be safely removed by a cardio-thoracic surgeon.
You are going to have surgery to remove a part of your lung because of lung cancer.
References

Frequently Asked Questions

What is the participant capacity for this research project?

"Affirmative. According to clinicaltrials.gov, an up-to-date record of this medical trial is being kept and the recruitment process has commenced since October 1st 2021. The research requires 10 individuals from a single study site to be enrolled in total." - Anonymous Online Contributor

Unverified Answer

Are there vacancies for participants in this investigation?

"Affirmative. Clinicaltrials.gov denotes that this medical research is actively searching for participants, having been first posted on October 1st 2021 and recently updated on March 21st 2022. At present, 10 individuals need to be enrolled from one specific site." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top